Combining a vaccine and T cell therapy to treat uveal melanoma
Official title: Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy
Funded at University of Tx Md Anderson Can Ctr · NIH-10669241 · Data updated 2026-11-12
This study is testing a new way to treat metastatic uveal melanoma by using a special vaccine and a personalized T cell therapy to help your immune system fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 20, 2022 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $218,011 |
| NIH project number | 5R01CA266714-02 |
| Project ID | NIH-10669241 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with metastatic uveal melanoma who have not responded adequately to existing treatments.
✕Less likely to help
Patients with non-melanoma cancers or those who have not been diagnosed with metastatic uveal melanoma may not benefit from this research.
What this research studies
This research investigates a new treatment approach for metastatic uveal melanoma by combining a specialized vaccine with adoptive T cell therapy. Patients will receive a tailored T cell product that targets a specific protein (PRAME) found in their tumors, along with a vaccine made from synthetic peptides designed to enhance the immune response. Additionally, an immune checkpoint inhibitor will be used to improve the effectiveness of the treatment by modifying the tumor environment. This innovative combination aims to improve patient outcomes by sustaining the activity of the immune cells against the cancer.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with metastatic uveal melanoma.
How similar studies have gone: Previous research has shown promise in combining immunotherapy approaches, suggesting potential for success with this novel treatment strategy.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Yee, Cassian — University of Tx Md Anderson Can Ctr
- Study coordinator: Yee, Cassian
Related research
Other NIH-funded projects on the same topics.
-
SOCS1's role in uveal melanoma response to immunotherapy
This project looks at whether levels of a protein called SOCS1 can predict and help improve immunotherapy response for people with uveal melanoma.
-
Understanding how SOCS1 affects uveal melanoma treatment with immunotherapy
This study is looking at how a protein called SOCS1 affects how well uveal melanoma patients respond to immunotherapy, with the hope of finding better ways to treat this tough cancer by understanding why current treatments aren't working as well as they should.
-
Targeting serotonin receptors to boost a cancer cell weakness in uveal melanoma
A small funding project tests whether blocking the serotonin HTR2B receptor can weaken mutant GNAQ/GNA11-driven uveal melanoma cells to help fight metastatic eye cancer.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
Dual mRNA therapeutics aimed at liver metastasis from uveal melanoma
A new approach uses two mRNA-based therapies designed to target liver metastases in adults with uveal melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.